These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 38402904)
1. Tumour-associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy. Wu Q; Mao H; Jiang Z; Tang D Immunology; 2024 Jul; 172(3):343-361. PubMed ID: 38402904 [TBL] [Abstract][Full Text] [Related]
2. Neutrophil diversity and plasticity in tumour progression and therapy. Jaillon S; Ponzetta A; Di Mitri D; Santoni A; Bonecchi R; Mantovani A Nat Rev Cancer; 2020 Sep; 20(9):485-503. PubMed ID: 32694624 [TBL] [Abstract][Full Text] [Related]
3. Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms. Liu C; He D; Li L; Zhang S; Wang L; Fan Z; Wang Y Pharmacol Res; 2022 Sep; 183():106364. PubMed ID: 35901939 [TBL] [Abstract][Full Text] [Related]
4. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287 [TBL] [Abstract][Full Text] [Related]
5. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment. Zhang Y; Guoqiang L; Sun M; Lu X Cancer Biol Med; 2020 Feb; 17(1):32-43. PubMed ID: 32296575 [TBL] [Abstract][Full Text] [Related]
6. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. Torphy RJ; Schulick RD; Zhu Y Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821 [TBL] [Abstract][Full Text] [Related]
7. Emerging Nanotechnology in Preclinical Pancreatic Cancer Immunotherapy: Driving Towards Clinical Applications. Pan X; Han T; Zhao Z; Wang X; Fang X Int J Nanomedicine; 2024; 19():6619-6641. PubMed ID: 38975321 [TBL] [Abstract][Full Text] [Related]
8. Microenvironmental regulation of tumor-associated neutrophils in malignant glioma: from mechanism to therapy. Wen J; Liu D; Zhu H; Shu K J Neuroinflammation; 2024 Sep; 21(1):226. PubMed ID: 39285276 [TBL] [Abstract][Full Text] [Related]
9. Emerging trends in the immunotherapy of pancreatic cancer. Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097 [TBL] [Abstract][Full Text] [Related]
10. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer. Wu J; Cai J Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943 [TBL] [Abstract][Full Text] [Related]
11. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy. Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253 [TBL] [Abstract][Full Text] [Related]
13. Metabolic Plasticity of Neutrophils: Relevance to Pathogen Responses and Cancer. Rogers T; DeBerardinis RJ Trends Cancer; 2021 Aug; 7(8):700-713. PubMed ID: 34023325 [TBL] [Abstract][Full Text] [Related]
14. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy. Luo W; Zheng L; Zhang T Int Immunopharmacol; 2021 Jan; 90():107199. PubMed ID: 33246828 [TBL] [Abstract][Full Text] [Related]
15. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Xue R; Zhang Q; Cao Q; Kong R; Xiang X; Liu H; Feng M; Wang F; Cheng J; Li Z; Zhan Q; Deng M; Zhu J; Zhang Z; Zhang N Nature; 2022 Dec; 612(7938):141-147. PubMed ID: 36352227 [TBL] [Abstract][Full Text] [Related]
16. Neutrophils as promising therapeutic targets in pancreatic cancer liver metastasis. Guo M; Sheng W; Yuan X; Wang X Int Immunopharmacol; 2024 Oct; 140():112888. PubMed ID: 39133956 [TBL] [Abstract][Full Text] [Related]
17. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889 [TBL] [Abstract][Full Text] [Related]
18. A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. Ge W; Yue M; Wang Y; Wang Y; Xue S; Shentu D; Mao T; Zhang X; Xu H; Li S; Ma J; Wang L; Cui J Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613599 [TBL] [Abstract][Full Text] [Related]
19. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669 [TBL] [Abstract][Full Text] [Related]
20. Neutrophil Heterogeneity in Cancer: From Biology to Therapies. Lecot P; Sarabi M; Pereira Abrantes M; Mussard J; Koenderman L; Caux C; Bendriss-Vermare N; Michallet MC Front Immunol; 2019; 10():2155. PubMed ID: 31616408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]